- Home
- WAI vs INKT Comparison
WAI vs INKT Comparison
Compare WAI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAI
- INKT
- Stock Information
- Founded
- WAI 2018
- INKT 2017
- Country
- WAI China
- INKT United States
- Employees
- WAI N/A
- INKT N/A
- Industry
- WAI
- INKT Medicinal Chemicals and Botanical Products
- Sector
- WAI
- INKT Health Care
- Exchange
- WAI NYSE
- INKT Nasdaq
- Market Cap
- WAI 28.2M
- INKT 31.2M
- IPO Year
- WAI 2023
- INKT 2021
- Fundamental
- Price
- WAI $2.20
- INKT $7.50
- Analyst Decision
- WAI
- INKT Strong Buy
- Analyst Count
- WAI 0
- INKT 2
- Target Price
- WAI N/A
- INKT $37.50
- AVG Volume (30 Days)
- WAI 55.7K
- INKT 3.7K
- Earning Date
- WAI 05-27-2025
- INKT 05-15-2025
- Dividend Yield
- WAI N/A
- INKT N/A
- EPS Growth
- WAI N/A
- INKT N/A
- EPS
- WAI N/A
- INKT N/A
- Revenue
- WAI $3,750,352.00
- INKT N/A
- Revenue This Year
- WAI N/A
- INKT N/A
- Revenue Next Year
- WAI N/A
- INKT N/A
- P/E Ratio
- WAI N/A
- INKT N/A
- Revenue Growth
- WAI N/A
- INKT N/A
- 52 Week Low
- WAI $2.30
- INKT $4.56
- 52 Week High
- WAI $20.00
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- WAI N/A
- INKT 48.04
- Support Level
- WAI N/A
- INKT $6.34
- Resistance Level
- WAI N/A
- INKT $7.76
- Average True Range (ATR)
- WAI 0.00
- INKT 0.58
- MACD
- WAI 0.00
- INKT 0.03
- Stochastic Oscillator
- WAI 0.00
- INKT 69.46
About WAI TOP KINGWIN LTD
Top KingWin Ltd operates as a corporate business training and consulting company, providing personal and management training and financial consulting services. It provides a number of essential business services in China to young and emerging companies including corporate business training services, which mainly focus on advanced knowledge and new perspectives on the capital markets; corporate consulting services, which mainly focus on various aspects of fundraising, and advisory and transaction services. Its main clients are entrepreneurs and executives in China's small and medium enterprises (SMEs).
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.